Lv41
620 积分 2025-02-26 加入
Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)
3小时前
待确认
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
23小时前
待确认
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
23小时前
待确认
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
1个月前
已完结
Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial
2个月前
已完结
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus Immunotherapy and targeted therapy in HCC
2个月前
已完结
Radiomics Quality Score 2.0: towards radiomics readiness levels and clinical translation for personalized medicine
2个月前
已完结
Attention-guided framework for integrative omics and temporal dynamics in predicting major pathological response in neoadjuvant immunochemotherapy for NSCLC
3个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
CT-Based Radiomics for Predicting PD-L1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
3个月前
已完结
皖公网安备34019202002308
